Platelet-derived growth factor and growth-promoting activity in the serum samples and platelets of patients with non-insulin-dependent diabetes mellitus

Naoki Nakashima, Fumio Umeda, Teruaki Yamauchi, Hidehiro Ishii, Akitaka Hisatomi, Hajime Nawata, Hideyuki Masuko, Kazuyuki Nakayama, Akinori Tatematsu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although platelet-derived growth factor (PDGF) is thought to be a major mediator of atherosclerotic disease, the pathophysiology of diabetic vasculopathy, including atheroscierosis, is unclear. By means of an enzyme immunoassay that used a monoclonal antibody against human PDGF-B chain, PDGF-like immunoreactivity was determined in serum, platelet-poor plasma, and platelet lysate of 28 patients with non-insulin-dependent diabetes mellitus and 11 control subjects. Growth-promoting activity was also measured by tritiated thymidine incorporation into DNA of cultured human fibroblasts. The PDGF-like immunoreactivity in serum was correlated (r = 0.42; p < 0.01) with that in platelet lysate prepared from a fixed volume of blood. Furthermore, a correlation (r = 0.70; p < 0.001) was found between the PDGF-like immunore-activity and the growth-promoting activity in platelet lysate but not in serum. There was no significant difference between patients with diabetes and control subjects with respect to the PDGF-like immunoreactivity in serum or in platelet lysate (36.2 ± 2.2 vs 42.8 ± 3.1 ng/ml or 49.1 ± 2.4 vs 56.2 ± 3.4 ng/mg protein; mean ± SEM). In contrast, the serum growth-promoting activity was lower (p < 0.05) in patients with diabetes than In control subjects (88.1% ± 7.1% vs 117.4% ± 6.9%) and there was a negative correlation (r = -0.39; p < 0.05) between the serum growth-promoting activity and the fasting plasma glucose level. The growth-promoting activity in platelet lysate of patients with diabetes did not differ from that of the control subjects (59.9% ± 11.6% vs 65.9% ± 11.2%). In platelet-poor plasma, the PDGF-like immunoreactivity was at the limit of detection (2 ng/ml) and the growth-promoting activity was consistently low. These results suggest that the PDGF quantities In serum samples and platelet lysate were not different in the diabetic state and that the low concentration of growth-promoting activity in diabetic serum was caused by an alteration in circulating factors other than PDGF.

Original languageEnglish
Pages (from-to)78-85
Number of pages8
JournalThe Journal of Laboratory and Clinical Medicine
Volume120
Issue number1
Publication statusPublished - Jan 1 1992

Fingerprint

Platelet-Derived Growth Factor
Medical problems
Platelets
Type 2 Diabetes Mellitus
Blood Platelets
Serum
Plasmas
Proto-Oncogene Proteins c-sis
growth promoting activity
Fibroblasts
Blood Volume
Immunoenzyme Techniques
Thymidine
Limit of Detection
Fasting
Blood
Monoclonal Antibodies
Glucose
Scanning electron microscopy
DNA

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Platelet-derived growth factor and growth-promoting activity in the serum samples and platelets of patients with non-insulin-dependent diabetes mellitus. / Nakashima, Naoki; Umeda, Fumio; Yamauchi, Teruaki; Ishii, Hidehiro; Hisatomi, Akitaka; Nawata, Hajime; Masuko, Hideyuki; Nakayama, Kazuyuki; Tatematsu, Akinori.

In: The Journal of Laboratory and Clinical Medicine, Vol. 120, No. 1, 01.01.1992, p. 78-85.

Research output: Contribution to journalArticle

Nakashima, Naoki ; Umeda, Fumio ; Yamauchi, Teruaki ; Ishii, Hidehiro ; Hisatomi, Akitaka ; Nawata, Hajime ; Masuko, Hideyuki ; Nakayama, Kazuyuki ; Tatematsu, Akinori. / Platelet-derived growth factor and growth-promoting activity in the serum samples and platelets of patients with non-insulin-dependent diabetes mellitus. In: The Journal of Laboratory and Clinical Medicine. 1992 ; Vol. 120, No. 1. pp. 78-85.
@article{4c5c7b64290d419f975211f6d8375e0d,
title = "Platelet-derived growth factor and growth-promoting activity in the serum samples and platelets of patients with non-insulin-dependent diabetes mellitus",
abstract = "Although platelet-derived growth factor (PDGF) is thought to be a major mediator of atherosclerotic disease, the pathophysiology of diabetic vasculopathy, including atheroscierosis, is unclear. By means of an enzyme immunoassay that used a monoclonal antibody against human PDGF-B chain, PDGF-like immunoreactivity was determined in serum, platelet-poor plasma, and platelet lysate of 28 patients with non-insulin-dependent diabetes mellitus and 11 control subjects. Growth-promoting activity was also measured by tritiated thymidine incorporation into DNA of cultured human fibroblasts. The PDGF-like immunoreactivity in serum was correlated (r = 0.42; p < 0.01) with that in platelet lysate prepared from a fixed volume of blood. Furthermore, a correlation (r = 0.70; p < 0.001) was found between the PDGF-like immunore-activity and the growth-promoting activity in platelet lysate but not in serum. There was no significant difference between patients with diabetes and control subjects with respect to the PDGF-like immunoreactivity in serum or in platelet lysate (36.2 ± 2.2 vs 42.8 ± 3.1 ng/ml or 49.1 ± 2.4 vs 56.2 ± 3.4 ng/mg protein; mean ± SEM). In contrast, the serum growth-promoting activity was lower (p < 0.05) in patients with diabetes than In control subjects (88.1{\%} ± 7.1{\%} vs 117.4{\%} ± 6.9{\%}) and there was a negative correlation (r = -0.39; p < 0.05) between the serum growth-promoting activity and the fasting plasma glucose level. The growth-promoting activity in platelet lysate of patients with diabetes did not differ from that of the control subjects (59.9{\%} ± 11.6{\%} vs 65.9{\%} ± 11.2{\%}). In platelet-poor plasma, the PDGF-like immunoreactivity was at the limit of detection (2 ng/ml) and the growth-promoting activity was consistently low. These results suggest that the PDGF quantities In serum samples and platelet lysate were not different in the diabetic state and that the low concentration of growth-promoting activity in diabetic serum was caused by an alteration in circulating factors other than PDGF.",
author = "Naoki Nakashima and Fumio Umeda and Teruaki Yamauchi and Hidehiro Ishii and Akitaka Hisatomi and Hajime Nawata and Hideyuki Masuko and Kazuyuki Nakayama and Akinori Tatematsu",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "120",
pages = "78--85",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Platelet-derived growth factor and growth-promoting activity in the serum samples and platelets of patients with non-insulin-dependent diabetes mellitus

AU - Nakashima, Naoki

AU - Umeda, Fumio

AU - Yamauchi, Teruaki

AU - Ishii, Hidehiro

AU - Hisatomi, Akitaka

AU - Nawata, Hajime

AU - Masuko, Hideyuki

AU - Nakayama, Kazuyuki

AU - Tatematsu, Akinori

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Although platelet-derived growth factor (PDGF) is thought to be a major mediator of atherosclerotic disease, the pathophysiology of diabetic vasculopathy, including atheroscierosis, is unclear. By means of an enzyme immunoassay that used a monoclonal antibody against human PDGF-B chain, PDGF-like immunoreactivity was determined in serum, platelet-poor plasma, and platelet lysate of 28 patients with non-insulin-dependent diabetes mellitus and 11 control subjects. Growth-promoting activity was also measured by tritiated thymidine incorporation into DNA of cultured human fibroblasts. The PDGF-like immunoreactivity in serum was correlated (r = 0.42; p < 0.01) with that in platelet lysate prepared from a fixed volume of blood. Furthermore, a correlation (r = 0.70; p < 0.001) was found between the PDGF-like immunore-activity and the growth-promoting activity in platelet lysate but not in serum. There was no significant difference between patients with diabetes and control subjects with respect to the PDGF-like immunoreactivity in serum or in platelet lysate (36.2 ± 2.2 vs 42.8 ± 3.1 ng/ml or 49.1 ± 2.4 vs 56.2 ± 3.4 ng/mg protein; mean ± SEM). In contrast, the serum growth-promoting activity was lower (p < 0.05) in patients with diabetes than In control subjects (88.1% ± 7.1% vs 117.4% ± 6.9%) and there was a negative correlation (r = -0.39; p < 0.05) between the serum growth-promoting activity and the fasting plasma glucose level. The growth-promoting activity in platelet lysate of patients with diabetes did not differ from that of the control subjects (59.9% ± 11.6% vs 65.9% ± 11.2%). In platelet-poor plasma, the PDGF-like immunoreactivity was at the limit of detection (2 ng/ml) and the growth-promoting activity was consistently low. These results suggest that the PDGF quantities In serum samples and platelet lysate were not different in the diabetic state and that the low concentration of growth-promoting activity in diabetic serum was caused by an alteration in circulating factors other than PDGF.

AB - Although platelet-derived growth factor (PDGF) is thought to be a major mediator of atherosclerotic disease, the pathophysiology of diabetic vasculopathy, including atheroscierosis, is unclear. By means of an enzyme immunoassay that used a monoclonal antibody against human PDGF-B chain, PDGF-like immunoreactivity was determined in serum, platelet-poor plasma, and platelet lysate of 28 patients with non-insulin-dependent diabetes mellitus and 11 control subjects. Growth-promoting activity was also measured by tritiated thymidine incorporation into DNA of cultured human fibroblasts. The PDGF-like immunoreactivity in serum was correlated (r = 0.42; p < 0.01) with that in platelet lysate prepared from a fixed volume of blood. Furthermore, a correlation (r = 0.70; p < 0.001) was found between the PDGF-like immunore-activity and the growth-promoting activity in platelet lysate but not in serum. There was no significant difference between patients with diabetes and control subjects with respect to the PDGF-like immunoreactivity in serum or in platelet lysate (36.2 ± 2.2 vs 42.8 ± 3.1 ng/ml or 49.1 ± 2.4 vs 56.2 ± 3.4 ng/mg protein; mean ± SEM). In contrast, the serum growth-promoting activity was lower (p < 0.05) in patients with diabetes than In control subjects (88.1% ± 7.1% vs 117.4% ± 6.9%) and there was a negative correlation (r = -0.39; p < 0.05) between the serum growth-promoting activity and the fasting plasma glucose level. The growth-promoting activity in platelet lysate of patients with diabetes did not differ from that of the control subjects (59.9% ± 11.6% vs 65.9% ± 11.2%). In platelet-poor plasma, the PDGF-like immunoreactivity was at the limit of detection (2 ng/ml) and the growth-promoting activity was consistently low. These results suggest that the PDGF quantities In serum samples and platelet lysate were not different in the diabetic state and that the low concentration of growth-promoting activity in diabetic serum was caused by an alteration in circulating factors other than PDGF.

UR - http://www.scopus.com/inward/record.url?scp=0026623117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026623117&partnerID=8YFLogxK

M3 - Article

VL - 120

SP - 78

EP - 85

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 1

ER -